A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Otsuka Pharmaceutical Development & Commercialization, Inc.400 enrolled

Overview

The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

400

Conditions

Schizophrenia and Schizoaffective Disorder

Interventions

AripiprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of schizophrenia or schizoaffective disorder being treated as outpatients,no response to past antipsychotic treatment and patients who symptoms are notoptimally controlled defined as CGI- S\<7 Exclusion Criteria: * pregnant or breastfeeding,patients at risk for committing suicide,diagnosis of mood disorders, delirium, dementia and other cognitive disorders,patients treatment resistant to otherantipyschotic medications and treatment with a long acting psychotic in which the last dose was within 3 months of treatment phase

Outcomes

Primary Outcomes

Clinical Global Impression-Improvement at endpoint

Secondary Outcomes

Clinical Global Impression scale

Investigator's Assessment Questionnaire

Patient preference of medication at endpoint

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.